Objectives-To consider the role of platinum and the relative merits of single agent and combination chemotherapy in the treatment of advanced ovarian cancer.
Introduction
Ovarian carcinoma is the seventh most common cancer of women in the world. Some 140 000 new cases are diagnosed every year and the disease is responsible for the greatest number of deaths from gynaecological malignancy in Europe and North America.' Despite over 50 randomised clinical trials having examined the relative efficacy of different chemotherapeutic regimens in advanced disease (FIGO (International Federation of Gynaecology and Obstetrics) stages III and IV), individually these trials have been too small to show clear benefit of one type of chemotherapy over another. Nevertheless, many of these trials have had an important influence on clinical practice, and consequently the type and intensity of chemotherapy used routinely for patients with advanced disease have fluctuated greatly.
Ovarian cancer was one of the first solid malignant tumours to be treated by chemotherapy, and the single alkylating agents that were first used over 30 years ago were considered optimal treatment until the mid1970s. The past 15 years, however, have seen many changes in disease management. In 1978 a small randomised trial in advanced disease found that Hexa-CAF, a combination of cytotoxic drugs (hexamethylmelamine, cyclophosphamide, methotrexate, and fluorouracil), achieved higher response rates than the single alkylating agent melphalan and suggested the possibility of a corresponding improvement in survival.2 At about the same time phase II studies suggested that cisplatin was the most promising new drug then available.' These results rapidly led to the standard use of cisplatin in combination with other cytotoxic drugs, usually doxorubicin and cyclophosphamide with or without hexamethylmelamine. 45 When, however, doubt was cast on the effectiveness of doxorubicin by both randomised phase III trials6-8 and phase II studies in patients not responding to cisplatin9 several major centres adopted cisplatin plus cyclophosphamide as standard. Furthermore, when other trials failed to find significant survival differences between single agent cisplatin and cisplatin in combination with other drugs'0 some centres reverted to using single agent platinum as routine first line treatment. Recently a large number of trials have compared cisplatin with its less nephrotoxic and neurotoxic analogue carboplatin, and although follow up times were often short, many institutions have now adopted carboplatin as standard.
Currently it is unclear what constitutes optimal chemotherapy for advanced disease and treatment strategies vary both nationally and internationally. What is clear is that to date no individual clinical trial has been large enough to detect survival differences of the magnitude that could reasonably be expected with available treatment.'2 Consequently the inconclusive results of over 50 such trials reported could be consistent with moderate treatment benefits.'3 The British Medical Research Council Gynaecological Cancer Working Party realised the need to synthesise the information from these trials to evaluate currently used chemotherapeutic regimens. Given the problems associated with a qualitative review of published work,'3 this group initiated an overview which used formal cluantitative methods to combine the results from all Available randomised trials examining the role of platinum and of combination chemotherapy in the treatment ofadvanced ovarian cancer. At the outset the MRC overview secretariat contacted the investigators responsible for each trial, inviting their collaboration. In so doing it established the Advanced Ovarian Cancer Trialists Group, under whose auspices the overview was conducted.
Methods and data
The relative merits of single agent and combination chemotherapy and the role of platinum in disease management were sought, and five comparisons between different forms of chemotherapy were identified as being of interest. These were: (I) single nonplatinum agent versus non-platinum combination; (II) single non-platinum agent versus platinum combination; (III) addition of platinum to a regimen; ( Fifty three eligible randomised trials were identified, two other potentially eligible studies having to be excluded on the ground that they did not seem to be appropriately randomised. At the time of data collection for the overview roughly 30% of these eligible trials had not been published fully. Information was available from the 45 studies listed in appendix A6 8 10 11 (unpublished references (A)- (F) ) and unavailable from the eight eligible trials listed in appendix B.25' Information was sought for each individual patient randomised in these studies, and the 45 available trials included data on 8139 patients (6408 deaths) originating from different countries. These patients accounted for 95% of all known patients entered into randomised clinical trials of chemotherapy in advanced ovarian carcinoma that met the overview criteria for eligibility.
In all but two cases the individual patient information that was supplied for studies was updated for the overview. Thus the overview used information from an extended period with, for example, a median follow up of 10 years in trials comparing non-platinum single agents with non-platinum combinations. Incoming data were checked for any obvious flaws or inconsistencies such as missing values, dates out of sequence, and apparent differences between the data set and publication. Problems were rectified by correspondence with the principal investigator. In order to avoid the potential bias of exclusion after randomisation it was necessary to recover data from patients who had been randomised but excluded from the analysis of Comparison II contained 13 eligible trials2529-365859 (unpublished references (A), (B)), of which data were available from 11. In these trials 659 patients were randomised to receive a single non-platinum drug and 670 to receive a platinum combination, although many of the patients allocated to the single agent received platinum on relapse. The median follow up period was 6 5 years and the total number of observed deaths 1136. The dose of cisplatin used in the combination arm of these trials ranged from 30 to 100 mg/M2, 50 combinations-was due to the three arm GICOG study (Gruppo Interegionale Cooperativo Oncologico Ginecologia)'°having utilised two different platinum combinations. A large proportion of patients in comparison IV (60%) were from that trial. A total of 712 deaths were observed, and the median follow up period was 6 5 years. One trial40 had a slightly different objective from the others, in that it compared high dose cisplatin (100 mg/m2) given as a single agent with low dose cisplatin (20 mg/m2) given in combination. In all other trials in comparison IV the dose of platinum was about equal in both arms and the dose of cisplatin did not exceed 60 mg/m2. The analysis in comparison IV was therefore performed both including and excluding that trial.
Results
All trials-The survival curves ( fig 7) suggested a difference in favour of the combination chemotherapy after two years, which was maintained until about year 8. The overall difference between the curves was not significant (X2=2-53; p=01 1). Likewise, the overall relative risk of 0-89 had a confidence interval straddling unity (95% confidence interval 0-76 to 1 -04) (fig 8) .
Excluding high dose-low dose study-After excluding the high dose-low dose study the difference between the two curves achieved borderline significance (X2=4-82; p=003), and the overall relative risk of 0 85 (95% confidence interval 0-72 to 1 00) (fig 8) platinum on relapse from which, arguably, they might derive a late benefit. The results of the analyses imply that platinum in combitation is more effective than single agent platinum in the doses used, particularly after two years. Notably, however, in most studies the dose of platinum used as a single agent was lower than is currently used. It will therefore be important to determine whether the apparent difference between treatments was due solely to the addition ofother drugs or was, in fact a question of dose as implied in the study by Wiltshaw et al."0 If so, patients receiving drug combinations fared better simply because they received a higher dose of drug irrespective of type.
Similar results and a similar problem of dose were found in a separate overview60 which examined the role of doxorubicin in ovarian carcinoma. That overview, which reviewed studies of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus cyclophosphamide and cisplatin (CP), found a significant survival advantage for patients treated with CAP over those treated with CP but also concluded that the observed difference might have been due simply to patients in the three drug combination arm having higher total doses of drugs. The only way to resolve this is by comparing currently favoured doses of single agent platinum with platinum combinations in a large prospective randomised clinical trial.
The results of the comparison of cisplatin and carboplatin (comparison V) offer no good evidence that cisplatin is either superior or inferior to carboplatin in terms of survival when given either as a single agent or in combination. Some of the trials included in this comparison, however, were at a comparatively early stage of follow up, so that although the information presented on the first four years was reliable, further follow up was required. It should also be noted that the trials included in comparison V used doses of carboplatin based on surface area rather than on renal clearance as currently recommended. 6 It is clear from the confidence intervals associated with the overall relative risks that even combining the results from many studies does not provide enough patients to make any firm statements about the rIsults of the comparisons except perhaps for the firsfbne.
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Consequently, although all of these comparisons were suggestive of treatment benefit associated with first line platinum based combination chemotherapy, no conclusive evidence emerges. Trials of about double the size of these would be required to establish reliably whether these trends represent actual treatment benefits. The comparison of cisplatin and carboplatin approaches such numbers of patients and provides reliable information on fairly short term survival (up to four years), although, as mentioned above, longer follow up is required. This uncertainty emphasises that in the past clinical trials have been an order -of magnitude too small to detect the size of differences which this overview suggests may be realistic for currently available chemotherapy regimens.
IMPLICATIONS
Arguably an overview using a cross section ofpatient types from many different trials is more likely to reflect the real world than an individual trial and therefore to estimate more accurately the type of treatment effects that are generally achievable. Even so, just as an individual trial cannot provide a prescription for treating any individual patient, neither can an overview. Nevertheless, a well conducted overview provides the least biased and most accurate summary of existing information from clinical trials, from which the clinician can make his or her own decisions about disease management.
Despite not being able to provide any firm conclusions about the most effective forms of treatment for advanced ovarian cancer, this overview raises three important hypotheses-namely, (a) platinum combinations are generally better than non-platinum regimens as first line treatment (comparisons II and III); (b) platinum combinations are generally better than single agent platinum when platinum is used in the same dose (comparison IV (this is supported by the results from the CAP/CP overview,' as if the combination of cyclophosphamide, doxorubicin, and cisplatin is superior to cyclophosphamide plus cisplatin it is likely to be superior to standard dose cisplatin alone)); (c) cisplatin and carboplatin are equally effective (comparison V).
At the first meeting of the Advanced Ovarian Cancer Trialists Group, held in June 1990, when the results of these analyses were presented in a preliminary form, consideration of the above hypotheses led to the proposal that it would be appropriate to compare the cyclophosphamide, doxorubicin, cisplatin regimen with optimal dose carboplatin in a large international trial. Such a comparison would have important implications for the management of advanced ovarian cancer. As discussed above, even a moderate improvement in survival could prolong the lives of thousands of women worldwide. A null result would be equally important as the lower toxicity of carboplatin when given as a single agent would almost certainly improve a patient's quality of life. An international trial, icon-2 (International collaborative ovarian neoplasm study), has now been set up to compare cyclophosphamide, doxorubicin, and cisplatin versus optimal dose carboplatin and aims at accruing 2000 patients worldwide. A series of independent parallel trials, each with closely similar protocols, are planned, the data from which will be pooled in a prospective overview. The new study will include centres that participated in this overview, but the trial is open to any clinician who wishes to enter patients either as an individual or as part of a group. At present icon-2 has been launched in the United Kingdom and Italy and is recruiting patients.
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to treatment B lie to the right. Individual trials indicating a statistically significant result at the p= 001 level, lie wholly to one side of the line, such that their confidence intervals will not straddle it.
When trials had multiple treatment arms and made more than one comparison of interest the patients from the relevant arms were included in each appropriate comparison, provided that there had been a direct randomisation between the treatment categories used. Thus two trials25 (unpublished reference (A)) are included in more than one comparison. In trials where more than one arm was of the same treatment category the patients in these arms were grouped together for analysis. For example, in the trial comparing cisplatin versus cisplatin plus cyclophosphamide versus cisplatin, cyclophosphamide, and doxorubicin'°the patients from the two combination arms were amalgamated and compared with the patients assigned single agent treatment. Two trials stopped randomising to certain arms early,2324 and a further two studies employed two separate randomisation schemes23 (unpublished We have recruited a cohort of patients with definite or possible familial hypercholesterolaemia, which will allow epidemiological, clinical, genetic, and metabolic studies to be performed in a well characterised population. We report the characteristics of 526 patients with definite familial hypercholesterolaemia and their mortality during the first 10 years of follow up. We have also used the information collected at registration to examine how useful the various criteria for selective measurement of cholesterol concentration suggested for use in cardiovascular screening programmes4 are in identifying such patients.
Patients and methods
Recruitment of patients to the Simon Broome Register of Familial Hyperlipidaemia began in 1980. Patients were registered by the participating lipid clinics, to which they had been referred by either general practitioners or hospital specialists. Three categories of patients were admitted to the register: those defined as having definite familial hypercholesterolaemia, whose families contained at least one member in whom tendon xanthomas were present; those with possible familial hypercholesterolaemia, whose families had no member affected with tendon xanthomas; and a much smaller group with severe hypertriglyceridaemia. We report on patients who were classified as having definite familial hypercholesterolaemia. This was defined as a total cholesterol concentration above 7-5 mmol/I or, when available, a low density lipoprotein cholesterol concentration
